Motens (Lacidipine)

Lacidipine selectively blocks L‑type calcium channels in the smooth muscle of blood vessels. By preventing calcium entry, it relaxes the vascular smooth muscle, causing vasodilation and a reduction in peripheral resistance, which leads to lower systolic and diastolic blood pressure.

The appropriate dose of Motens is determined by the prescribing healthcare professional based on the individual’s clinical condition, response to therapy, and any concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose without medical advice.

Safety data for Lacidipine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their healthcare provider.

To request Motens, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Motens (Lacidipine) is a dihydropyridine calcium channel blocker, offering potent vasodilation with a relatively long half‑life. Compared with other classes such as ACE inhibitors or beta‑blockers, it primarily reduces peripheral resistance without significant effects on heart rate, making it suitable for patients who need strong blood‑pressure control and tolerate calcium‑channel‑blocker side‑effects.

Motens should be stored at ambient temperature below 25 °C, in its original packaging, protected from moisture and direct light. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

Motens is taken orally, usually once daily, with or without food as directed by a healthcare professional. Swallow the tablet whole with a glass of water; do not crush, chew, or split the tablet unless specifically instructed by a prescriber.

The most serious risks include severe hypotension, which can cause fainting or shock, and rare but potentially life‑threatening reactions such as angioedema, myocardial infarction, or significant liver enzyme elevations. Patients should seek immediate medical attention if they experience swelling of the face or throat, chest pain, or sudden weakness.

Motens is contraindicated in patients with known hypersensitivity to Lacidipine or any other calcium channel blocker, and in those with severe aortic stenosis or unstable angina. Caution is also advised for individuals with severe hepatic impairment, as drug clearance may be reduced.